AzTrials
AzTrials

Multiple SclerosisPhase 2AFFINITYNCT03222973

Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)

A Phase 2 study testing BIIB033 (opicinumab) in people with Multiple Sclerosis, run by Biogen at 159 sites in 15 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The primary objective of Part 1 of this study is to evaluate the effects of BIIB033 versus placebo on disability improvement over 72 weeks. The primary objective of Part 2 of this study is to evaluate the long-term safety profile of BIIB033 as an add-on therapy in participants with MS. Read more about this study

Who is it for?
Ages 18 to 58 years
Conditions the study is for
Multiple Sclerosis
What is being tested?
BIIB033 (opicinumab)
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
263 participants
Where
159 sitesin 15 countries
Study dates
15 Nov 2017to 12 Feb 2021
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 58 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Baseline Expanded Disability Status Scale (EDSS) of 2.0 to 6.0, have a diagnosis of relapsing-remitting multiple sclerosis (RRMS) per the 2010 McDonald's criteria or onset of secondary progressive multiple sclerosis (SPMS) per the Lublin and Reingold criteria, and should have experienced their first MS symptom(s) within the previous 20 years.
  • Subjects must have experienced at least 1 of the following within 24 months prior to Day 1/Baseline: a clinical relapse (but not within 24 weeks prior to Day 1/Baseline), gadolinium-enhancing lesions on brain or spinal cord magnetic resonance imaging (MRI), or new T2 lesion(s) on brain or spinal cord MRI.
  • Subjects must be on a stable dose of a protocol-specified anti-inflammatory disease-modifying therapy (DMT) (IFNβ [Avonex, Plegridy, Betaferon/Betaseron, or Rebif], dimethyl fumarate (DMF) [Tecfidera], or natalizumab [Tysabri]) for at least 24 weeks prior to enrollment.
  • In addition, subjects must have met protocol-defined MRI characteristics using magnetization transfer ratio (MTR) and diffusion tensor imaging (DTI) sequences at Screening/Baseline.
  • -Subjects who complete study treatment (BIIB033 or placebo) at Part 1/Week 72 Visit.

Who cannot join

  • Primary progressive MS
  • An MS relapse that has occurred within 24 weeks prior to Day 1/Baseline or the subject has not stabilized from a previous relapse at the time of Screening.
  • Treatment with any chemotherapeutic agents (e.g., mitoxantrone, cyclophosphamide, cladribine), cell-depleting monoclonal antibodies (mAbs) (e.g., rituximab, ocrelizumab, alemtuzumab), total lymphoid irradiation, T-cell or T-cell receptor vaccination, or teriflunomide within 1 year prior to Day 1/Baseline.
  • Treatment with other anti-inflammatory DMTs (e.g., GA, fingolimod, daclizumab) or plasmapheresis within 24 weeks prior to Day1/Baseline.
  • Treatment with Botox for limb spasticity within 24 weeks before Day 1/Baseline.
  • Contraindications to MRI, for example, presence of pacemakers or other implanted metal devices (excluding dental braces), an allergy to gadolinium renal impairment, or claustrophobia that cannot be medically managed.
Show all 14Show fewer
  • History of human immunodeficiency virus or other immunodeficient conditions.
  • History of malignancy; however, subjects with a history of excised or treated basal cell carcinoma or fewer than 3 squamous cell carcinomas are eligible to participate in this study.
  • Subjects who did not complete study treatment in Part 1/Week 72 Visit
  • Subjects who have a duration >12 weeks between their Part 1/Week 72 Visit and Part 2/Day 1.
  • Contraindications to MRI, for example, presence of pacemakers or other implanted metal devices (excluding dental braces), an allergy to Gd, renal impairment, or claustrophobia that cannot be medically managed.
  • History of human immunodeficiency virus or other immunodeficient conditions not related to DMT treatment.
  • History of malignancy unless enrollment is approved by the Sponsor; subjects with a history of excised or treated basal cell carcinoma or fewer than 3 squamous cell carcinomas are eligible to participate in this study.
  • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Trial locations and contacts

159 sites in 15 countries.

159 sites in 15 countries

United States51 sites
  • Research Site

    Atlanta, Georgia, 30309

  • Research Site

    Baltimore, Maryland, 21287

  • Research Site

    Berkeley, California, 94705

  • Research Site

    Boston, Massachusetts, 02114

  • Research Site

    Boston, Massachusetts, 02215

  • Research Site

    Centennial, Colorado, 80112

  • Research Site

    Chicago, Illinois, 60612

  • Research Site

    Chicago, Illinois, 60637

  • Research Site

    Columbus, Ohio, 43214

  • Research Site

    Cullman, Alabama, 35058

  • Research Site

    Dallas, Texas, 75390-8806

  • Research Site

    Dayton, Ohio, 45417

  • Research Site

    Durham, North Carolina, 27710

  • Research Site

    Farmington Hills, Michigan, 48334

  • Research Site

    Fort Collins, Colorado, 80528

  • Research Site

    Freehold, New Jersey, 07728

  • Research Site

    Gilbert, Arizona, 85234

  • Research Site

    Houston, Texas, 77030

  • Research Site

    Knoxville, Tennessee, 37922

  • Research Site

    Las Vegas, Nevada, 89106

  • Research Site

    Latham, New York, 12110

  • Research Site

    Lexington, Kentucky, 40513

  • Research Site

    Lexington, Massachusetts, 01805

  • Research Site

    Long Beach, California, 90806

  • Research Site

    Memphis, Tennessee, 38018

  • Research Site

    Minneapolis, Minnesota, 55422

  • Research Site

    New York, New York, 10021

  • Research Site

    Newport Beach, California, 92663

  • Research Site

    Oklahoma City, Oklahoma, 73104

  • Research Site

    Orange, California, 92868

  • Research Site

    Orem, Utah, 84058

  • Research Site

    Overland Park, Kansas, 66212

  • Research Site

    Patchogue, New York, 11772

  • Research Site

    Pittsburgh, Pennsylvania, 15213

  • Research Site

    Portland, Oregon, 97225

  • Research Site

    Raleigh, North Carolina, 27607

  • Research Site

    Rochester, New York, 14642

  • Research Site

    Round Rock, Texas, 78681

  • Research Site

    Salt Lake City, Utah, 84103

  • Research Site

    Seattle, Washington, 98122

  • Research Site

    Seattle, Washington, 98133

  • Research Site

    St Louis, Missouri, 63110

  • Research Site

    St Louis, Missouri, 63131

  • Research Site

    Stamford, Connecticut, 06905

  • Research Site

    Stony Brook, New York, 11794

  • Research Site

    Sunrise, Florida, 33351

  • Research Site

    Tampa, Florida, 33612

  • Research Site

    Teaneck, New Jersey, 07666

  • Research Site

    Washington D.C., District of Columbia, 20007

  • Research Site

    Wellesley, Massachusetts, 02481

  • Research Site

    Willow Grove, Pennsylvania, 19090

Other trials in United States

United Kingdom14 sites
  • Research Site

    Brighton, BN2 5BE

  • Research Site

    Exeter, Devon, EX2 5DW

  • Research Site

    Glasgow, Strathclyde, G51 4TF

  • Research Site

    Leeds, West Yorkshire, LS1 3EX

  • Research Site

    Liverpool, Merseyside, L9 7LJ

  • Research Site

    London, Greater London, SE5 9RS

  • Research Site

    London, Greater London, W6 8RF

  • Research Site

    Newcastle upon Tyne, Tyne & Wear, NE1 4LP

  • Research Site

    Nottingham, Nottinghamshire, NG7 2UH

  • Research Site

    Oxford, Oxfordshire, OX3 9DU

  • Research Site

    Plymouth, Devon, PL6 8DH

  • Research Site

    Salford, Greater Manchester, M6 8HD

  • Research Site

    Sheffield, S10 2JF

  • Research Site

    Swansea, SA6 6NL

Other trials in United Kingdom

Italy13 sites
  • Research Site

    Cefalù, Palermo, 90015

  • Research Site

    Genova, 16132

  • Research Site

    Messina, 98124

  • Research Site

    Milan, 20132

  • Research Site

    Milan, 20133

  • Research Site

    Montichiari, Brescia, 25018

  • Research Site

    Naples, 80055

  • Research Site

    Naples, 80131

  • Research Site

    Naples, 80138

  • Research Site

    Pisa, 56126

  • Research Site

    Pozzilli, Isernia, 86077

  • Research Site

    Roma, 185

  • Research Site

    Verona, 37134

Other trials in Italy

France11 sites
  • Research Site

    Amiens, Somme, 80054

  • Research Site

    Bordeaux, Gironde, 33076

  • Research Site

    Bron, Rhone, 69500

  • Research Site

    Clermont-Ferrand, Puy De Dome, 63003

  • Research Site

    Lille, Nord, 59000

  • Research Site

    Montpellier, Herault, 34295

  • Research Site

    Nantes, Loire Atlantique, 44093

  • Research Site

    Nîmes, Gard, 30029

  • Research Site

    Paris, 75013

  • Research Site

    Strasbourg, Bas Rhin, 67098

  • Research Site

    Toulouse, Haute Garonne, 31059

Other trials in France

Germany10 sites
  • Research Site

    Berlin, 10117

  • Research Site

    Bochum, North Rhine-Westphalia, 44791

  • Research Site

    Dresden, Saxony, 1307

  • Research Site

    Düsseldorf, North Rhine-Westphalia, 40225

  • Research Site

    Freiburg im Breisgau, Baden-Wurttemberg, 79106

  • Research Site

    Munich, Bavaria, 81675

  • Research Site

    Münster, 48149

  • Research Site

    Trier, Rhineland-Palatinate, 54292

  • Research Site

    Tübingen, Baden-Wurttemberg, 72076

  • Research Site

    Ulm, Baden-Wurttemberg, 89081

Other trials in Germany

Poland10 sites
  • Research Site

    Bydgoszcz, 85-795

  • Research Site

    Gdansk, 80-803

  • Research Site

    Katowice, 40-571

  • Research Site

    Katowice, 40-650

  • Research Site

    Krakow, 31-637

  • Research Site

    Lodz, 90-324

  • Research Site

    Lublin, 20-954

  • Research Site

    Szczecin, 70-111

  • Research Site

    Warsaw, 04-749

  • Research Site

    Zabrze, 41-800

Other trials in Poland

Spain9 sites
  • Research Site

    Barakaldo, Vizcaya, 48903

  • Research Site

    Barcelona, 08907

  • Research Site

    Barcelona, 8035

  • Research Site

    Barcelona, 8036

  • Research Site

    Córdoba, 14004

  • Research Site

    Madrid, 28006

  • Research Site

    Majadahonda, Madrid, 28222

  • Research Site

    Salt, Girona, 17190

  • Research Site

    Seville, 41009

Other trials in Spain

Canada8 sites
  • Research Site

    Edmonton, Alberta, T6G 1Z1

  • Research Site

    Gatineau, Quebec, J8Y 1W2

  • Research Site

    Longueuil, Quebec, J4V2J2

  • Research Site

    Montreal, Quebec, H3A 2B4

  • Research Site

    Ottawa, Ontario, K1H8L6

  • Research Site

    Toronto, Ontario, M5B1W8

  • Research Site

    Vancouver, British Columbia, V6T 1Z3

  • Research Site

    Victoria, British Columbia, V8R 1J8

Other trials in Canada

Australia7 sites
  • Research Site

    Box Hill, Victoria, 3128

  • Research Site

    Clayton, Victoria, 3168

  • Research Site

    Heidelberg, Victoria, 3084

  • Research Site

    Melbourne, Victoria, 3004

  • Research Site

    New Lambton Heights, NS 2305

  • Research Site

    Parkville, Victoria, 3050

  • Research Site

    Westmead, 2145

Other trials in Australia

Belgium7 sites
  • Research Site

    Bruges, 8000

  • Research Site

    Brussels, 1090

  • Research Site

    Brussels, 1200

  • Research Site

    Ghent, 9000

  • Research Site

    La Louvière, 7100

  • Research Site

    Leuven, 3000

  • Research Site

    Roeselare, 8800

Other trials in Belgium

Czechia6 sites
  • Research Site

    Brno, 65691

  • Research Site

    Brno, 66491

  • Research Site

    Hradec Králové, 50005

  • Research Site

    Jihlava, 58601

  • Research Site

    Pardubice, 53203

  • Research Site

    Prague, 12808

Other trials in Czechia

Hungary6 sites
  • Research Site

    Budapest, 1135

  • Research Site

    Budapest, 1145

  • Research Site

    Budapest, H-1204

  • Research Site

    Esztergom, 2500

  • Research Site

    Kistarcsa, 2143

  • Research Site

    Pécs, 7623

Other trials in Hungary

Switzerland5 sites
  • Research Site

    Aarau, 5001

  • Research Site

    Basel, 4031

  • Research Site

    Bern, 3010

  • Research Site

    Lugano, 6903

  • Research Site

    Zurich, 8091

Other trials in Switzerland

Israel1 site
  • Research Site

    Ramat Gan, 5262000

Other trials in Israel

Netherlands1 site
  • Research Site

    Geleen, 6162 AP

Other trials in Netherlands

About this study

Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies

The primary objective of Part 1 of this study is to evaluate the effects of BIIB033 versus placebo on disability improvement over 72 weeks. The primary objective of Part 2 of this study is to evaluate the long-term safety profile of BIIB033 as an add-on therapy in participants with MS.

The secondary objective of Part 1 is to evaluate the effects of BIIB033 versus placebo on additional measures of disability improvement. The secondary objective of Part 2 is to investigate long-term efficacy (disability improvement) and additional safety measures of BIIB033 as an add-on therapy in participants with MS.

Being tested
BIIB033 (opicinumab), Placebo
Keywords
Remyelination, Re-myelination, DMT, LINGO-1, Anti-LINGO-1, Opicinumab
Medical subject headings
Multiple Sclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BIIB033 (opicinumab)Drug

    Administered as specified in the treatment arm

  • PlaceboDrug

    Administered as specified in the treatment arm

Study groups in NCT03222973
Study groupRoleWhat they receive
BIIB033 (opicinumab) 750 mgExperimentalParticipants with relapsing multiple sclerosis (RMS) will receive BIIB033 750 milligram (mg) intravenously (IV) as an add-on therapy to a background disease-modifying therapy (DMT) once every 4 weeks over 72 weeks in Part 1 and once every 4 weeks over 96 weeks in Part 2.
Receives: Drug: BIIB033 (opicinumab)
PlaceboPlacebo comparatorParticipants with RMS will receive placebo IV as an add-on therapy to a background DMT once every 4 weeks over 72 weeks in Part 1 and BIIB033 once every 4 weeks over 96 weeks in Part 2. The placebo looks like BIIB033 but does not contain the active ingredient that is thought to have an effect on MS disease. The placebo used in this study is sterile normal saline (water with a small amount of sodium chloride [salt]).
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Part 1: Overall Response Score

    Overall Response Score is a multicomponent score based on 4 components: Expanded Disability Status Scale (EDSS), Timed 25-Foot Walk (T25FW), 9-Hole Peg Test in the dominant hand (9HPT-D), and 9HPT in the nondominant hand (9HPT-ND). Overall Score was sum of 4 components at each visit and ranges from +4 (improvement) to -4 (worsening). At each visit, each component is given a score relative to baseline (BL): -1 if threshold is met for worsening, 0 if no changes meet threshold criteria, or +1 if threshold is met for improvement. For T25FW and 9HPT improvement is ≥15% decrease in time from BL and worsening is ≥15% increase in time from BL. For EDSS, improvement is: ≥1.0-point decrease in EDSS from a BL score of ≤6.0, and worsening is defined as a ≥1-point increase from a BL score of ≤5.5 or a ≥0.5-point increase from a BL score equal to 6.0. Positive Overall Response Score indicated that there was improvement in more components than there was worsening.

    Measured: Part 1: Baseline to Week 72

  2. Part 2: Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A SAE is any untoward medical occurrence that at any dose results in death, life-threatening event, requires inpatient hospitalization, significant disability/incapacity or congenital anomaly.

    Measured: Part 2: Baseline to Week 169

Secondary outcomes (16)
  1. Part 1: Percentage of Participants With 12-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND

    EDSS measures disability status over time in MS on a scale ranging from 0 to 10, with higher scores indicating more disability. For EDSS, improvement is defined as a ≥1.0-point decrease in EDSS from a BL score of ≤6.0. T25FW is a quantitative mobility and leg function performance test based on a timed walk over 25 feet that is averaged between two completed trials. Longer time indicates slower walking. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs. Longer time indicates poorer upper limb function. For T25FW and 9HPT ≥15% decrease in time from BL indicates improvement.

    Measured: Part 1: Baseline to Week 72

  2. Part 1: Percentage of Participants With 12-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, 9HPT-ND, or 3-Second Paced Auditory Serial Addition Test (PASAT-3)

    EDSS measures disability status over time in MS (scale range: 0-10), higher scores=more disability and improvement defined as ≥1.0-point decrease in EDSS from BL score ≤6.0. T25FW is quantitative mobility and leg function performance test, where timed walk over 25 feet that is averaged between two completed trials. Longer time=slower walking. 9HPT is quantitative test of upper extremity function, measures time to place 9 pegs into 9 holes and then remove pegs. Longer time=poorer upper limb function. PASAT assesses auditory information processing speed. In 3-second PASAT, numbers are presented at a rate of 1 every 3 seconds with scores (range 0-120), higher scores=better working memory. For T25FW and 9HPT ≥15% decrease in time from BL is improvement. For PASAT ≥15% increase from BL is improvement.

    Measured: Part 1: Baseline to Week 72

  3. Part 1: Percentage of Participants With 12-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND, and Without Confirmed Worsening in Any of the 4 Assessments During the 72 Weeks of the Study

    EDSS measures disability status over time in MS on a scale ranging from 0 to 10, with higher scores indicating more disability. For EDSS, improvement is defined as a ≥1.0-point decrease in EDSS from a BL score of ≤6.0, and worsening is defined as a ≥1-point increase from a BL score of ≤5.5 or a ≥0.5-point increase from a BL score equal to 6.0. T25FW is a quantitative mobility and leg function performance test based on a timed walk over 25 feet that is averaged between two completed trials. Longer time indicates slower walking. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs. Longer time indicates poorer upper limb function. For T25FW and 9HPT ≥15% decrease in time from BL indicates improvement and ≥15% increase in time from BL indicates worsening.

    Measured: Part 1: Baseline to Week 72

  4. Part 1: Percentage of Participants With 12-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, 9HPT-ND, and Symbol Digit Modalities Test (SDMT)

    EDSS measures disability status over time in MS on a scale (range 0-10), higher scores=more disability. For EDSS, improvement is: a ≥1.0-point decrease in EDSS from a BL score of ≤6.0. T25FW is a quantitative mobility and leg function performance test based on a timed walk over 25 feet that is averaged between two completed trials. Longer time=slower walking. 9HPT is quantitative test of upper extremity function that measures time it takes to place 9 pegs into 9 holes and then remove pegs. Longer time=poorer upper limb function. For T25FW and 9HPT ≥15% decrease in time from BL indicates improvement. The SDMT measures time to pair abstract geometric symbols with specific numbers. The score is the number of correctly coded items (range 0-110) in 90 seconds, higher scores=better outcome. Improvement is: ≥4-point increase from BL.

    Measured: Part 1: Baseline to Week 72

  5. Part 1: Percentage of Participants With 12-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND (20% Thresholds for T25FW and 9HPT)

    EDSS measures disability status over time in MS on a scale ranging from 0 to 10, with higher scores indicating more disability. For EDSS, improvement is defined as a ≥1.0-point decrease in EDSS from a BL score of ≤6.0. T25FW is a quantitative mobility and leg function performance test based on a timed walk over 25 feet that is averaged between two completed trials. Longer time indicates slower walking. The 9HPT is a quantitative test of upper extremity function that measures the time it takes to place 9 pegs into 9 holes and then remove the pegs. Longer time indicates poorer upper limb function. For T25FW and 9HPT ≥15% decrease in time from BL indicates improvement.

    Measured: Part 1: Baseline to Week 72

  6. Part 2: Overall Response Score

    Measured: Part 2: Baseline to Week 96

  7. Part 2: Percentage of Participants With 24-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND

    Measured: Part 2: Baseline to Week 108

  8. Part 2: Percentage of Participants With 24-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, 9HPT-ND, or PASAT-3

    Measured: Part 2: Baseline to Week 108

  9. Part 2: Percentage of Participants With 24-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND, and Without Confirmed Worsening in Any of the 4 Assessments During the 96 Weeks of the Study

    Measured: Part 2: Baseline to Week 96

  10. Part 2: Percentage of Participants With 24-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, 9HPT-ND, and SDMT

    Measured: Part 2: Baseline to Week 108

  11. Part 2: Percentage of Participants With 24-week Confirmed Improvement in at Least 1 of the Following Assessments: EDSS, T25FW, 9HPT-D, or 9HPT-ND (20% Thresholds for T25FW and 9HPT)

    Measured: Part 2: Baseline to Week 108

  12. Part 2: Number of Participants With Potentially Clinically Significant Abnormal Laboratory Values

    Laboratory assessments including hematology and blood chemistry were evaluated for safety. Criteria for abnormality: In 10^9/liter (L) [white blood cells <3.0/>16, neutrophils <1.5/ >13.5, lymphocytes <0.8/ >12, monocytes >2.5, eosinophils >1.6, basophils >1.6, platelets <=75/ >=700], hemoglobin <=95 [female (F)] or <=115 [male (M)] or >=175 (F) or >=190 (M) gram per liter (g/L), hematocrit <=32 (F) or <=37 (M) or >=54 (F) or >=60 (M) percentage (%), red blood cells <=3.5/ >=6.4 10^12/L, in millimoles per liter (mmol/L) [sodium <=126/ >=156, potassium <=3/ >=6, chloride <=90/ >=118, bicarbonate <=16/ >=35, calcium <=2/ >=3, phosphorous <=0.5491/ >=1.7119, glucose (non-fasting) <=2.2/>=13.75], AST/SGOT >=3x upper limit of normal (ULN), ALT/SGPT >=3xULN, alkaline phosphatase >=3xULN, creatinine >=1.5xULN, total bilirubin >=1.5xULN, total protein <=45/ >=100 g/L, albumin <=25 g/L, uric acid >=501.5 (F)/>=619.5 (M) micromole (umol)/L

    Measured: Part 2: Baseline to Week 96

  13. Part 2: Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Values

    The ECG result was classified as "normal", "abnormal", "abnormal, not adverse event", or "abnormal, adverse event". Shift to 'abnormal, not adverse event' included shift from normal or unknown to 'abnormal, not adverse event'. Shift to 'abnormal, adverse event' included shift from normal or unknown to 'abnormal, adverse event'.

    Measured: Part 2: Baseline to Week 96

  14. Part 2: Percentage of Participants With Potentially Clinically Significant Abnormal Vital Signs Values

    Vital sign measurements including temperature, pulse rate (supine), systolic blood pressure (BP) and diastolic (supine) BP were evaluated for safety. Criteria for abnormalities: Temperature: >38 degree celsius (◦C) or >=1 ◦C increase from baseline (BL); Pulse: [>100 beats per minute (bpm) or increase from BL of >30 bpm] or (<40 bpm or decrease from BL of >20 bpm); Systolic BP: [>160 millimeters of mercury (mmHg)/increase from BL of >40 mmHg] or (<90 mmHg/decrease from BL of >30 mmHg); Diastolic BP: (>100 mmHg/increase from BL of >30 mmHg) or (<45 mmHg/decrease from BL of >20 mmHg).

    Measured: Part 2: Baseline to Week 96

  15. Part 2: Percentage of Participants With Potentially Clinically Significant Abnormal Weight Values

    Criteria for abnormality was defined as a >7% increase or decrease in weight at the specified time point.

    Measured: Part 2: Baseline, Week 12, 24, 36, 48, 72 and 96

  16. Part 2: Number of Participants With Columbia Suicide Severity Rating Scale (C-SSRS) Score at Any Post-Baseline Visit

    C-SSRS systematically assess suicidal ideation and behavior rating scale. It rates an individual's degree of suicidal ideation on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent and behaviors". The scale identifies specific behaviors ranging from "preparatory acts or behavior" to "suicide" which may be indicative of an individual's intent to complete suicide.

    Measured: Part 2: Baseline to Week 96

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Jul 2017
  2. Study start15 Nov 2017
  3. Primary completion12 Feb 2021
  4. Study completion12 Feb 2021

Why it stopped: The top-line results from the Part 1 did not meet the pre-specified primary endpoint nor the key secondary endpoints. The decision to discontinue study 215MS202 Part 2 was not based on safety concerns.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
263 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03222973
Sponsor's protocol ID
215MS202
Other IDs
2017-001224-22, 2017
Acronym
AFFINITY
Status last verified
Mar 2022
First submitted
17 Jul 2017
Last updated
28 Apr 2022
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Publications

  • Calabresi PA, Giovannoni G, Hartung HP, Naismith RT, Fox RJ, Sormani MP, Arnold DL, Kappos L, Valis M, Newsome SD, Belkin MI, Bartholome E, Riester K, Javor A, Lyons J, Bradley DP, Fisher E, Tagge I, Naylor ML, Belachew S, Deykin A, Franchimont N, Zhu B, Cheng W. Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial. Mult Scler. 2026 Jan;32(1):107-120. doi: 10.1177/13524585251396433. Epub 2025 Dec 26.

    PubMed 41454463
  • Elliott C, Rudko DA, Arnold DL, Fetco D, Elkady AM, Araujo D, Zhu B, Gafson A, Tian Z, Belachew S, Bradley DP, Fisher E. Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis. Mult Scler. 2023 May;29(6):680-690. doi: 10.1177/13524585231162262. Epub 2023 Apr 10.

    PubMed 37036134
  • Hanf KJM, Arndt JW, Liu Y, Gong BJ, Rushe M, Sopko R, Massol R, Smith B, Gao Y, Dalkilic-Liddle I, Lee X, Mojta S, Shao Z, Mi S, Pepinsky RB. Functional activity of anti-LINGO-1 antibody opicinumab requires target engagement at a secondary binding site. MAbs. 2020 Jan-Dec;12(1):1713648. doi: 10.1080/19420862.2020.1713648.

    PubMed 31928294

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing BIIB033 (opicinumab) in people with Multiple Sclerosis, run by Biogen at 159 sites in 15 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 28 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 159 sites in United States, United Kingdom, Italy, France, Germany and 10 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 28 Apr 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Part 1: Overall Response Score (time frame: Part 1: Baseline to Week 72). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03222973, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Apr 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in